Perrigo Ends 2017 As It Started: Earnings Results Delayed
The OTC drug, nutritional products and Rx generics manufacturer reported interim and unaudited results for 2017 and said it will release its entire earnings statement on a date yet to be determined because "it needs additional time to complete its final income tax review procedures related to reconciliations of specific non-cash items.2018 begins with new CEO Uwe Rohrhoff at the helm.